- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00407654
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the response rate (complete and partial) in patients with previously treated metastatic colorectal cancer treated with VEGF Trap.
II. Determine the incidence of disease stabilization, in terms of 4-month progression-free survival, in patients treated with this drug.
SECONDARY OBJECTIVES:
I. Determine the median survival time of patients treated with this drug. II. Determine the 1-year survival rate and stable disease rate in patients treated with this drug.
III. Determine the response or stable disease duration in patients treated with this drug.
IV. Determine the toxicity of this drug in these patients. V. Determine the time to disease progression in patients treated with this drug.
VI. Determine if changes in free VEGF Trap levels correlate with response or toxicity.
OUTLINE: This is a multicenter, open-label study.
Patients are stratified according to prior bevacizumab treatment (yes vs no). Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection at the beginning of each course and at 60 days after completion of study treatment. Samples are analyzed by immunoenzyme techniques to determine the pharmacokinetics of VEGF Trap.
After completion of study treatment, patients are followed at 30 and 60 days and then every 3 months thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- histologically/cytologically confirmed metastatic colorectal metastatic cancer
- measurable disease (at least 1 lesion accurately measured in at least 1 dimension (longest diameter) as>20mm with conventional techniques or as >10mm with spiral CT scan
- >=4 weeks from major surgery
- at least 1prior line of systemic therapy for metastatic disease. Prior treatment with anti-epidermal growth factor receptor inhibitors is allowed. Last dose >=4 weeks prior to randomization
- Two cohorts: 1) bevacizumab naïveand; 2) bevacizumab treated
- May have received prior thymidylate synthetase inhibitor concurrently with radiation as "radiation sensitizer". Last dose >=4 weeks prior to randomization
- Prior radiation treatment >=4 weeks prior to randomization
- Age>=18 years
- Life expectancy >=3 months
- ECOG<=2 (Karnofsky=60%)
- leukocytes >3.0x10^9/L
- absolute neutrophil count >1.5 x 10^9/L
- platelets>75x10^9/L
- INR <1.5 unless on warfarin
- total bilirubin within 1.5xULN
- AST/ALT≤2.5 X institution ULN
- creatinine≤1.5xULN OR creatinine clearance >60mL/min/1.73m2 for patients with creatinine levels above1.5x institution limits
- Urinalysis negative for protein OR 24h urine for protein <500 mg
- full-dose anticoagulants with PT INR >1.5 eligible provided that: a) patient is therapeutic on stable dose of warfarin or low molecular weight heparin; b) patients on warfarin, the upper target for INR is <=3; c) no active bleeding/pathological condition carrying high bleeding risk
- Eligibility of patients receiving medications known to affect activity/PK of VEGF Trap will be determined by PI
- Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 6 months after completion of VEGF Trap therapy
- Ability to understand/willingness to sign written informed consent
Exclusion Criteria:
- chemotherapy/radiotherapy within 4 weeks (6 weeks for nitrosoureas/mitomycin C) prior to study entry
- Other investigational agents concurrently
- History of prior anti-angiogenic therapy other than bevacizumab
- Evidence of CNS disease
- Known hypersensitivity to Chinese hamster ovary cell products/other recombinant human antibodies, and patients with a history of allergic reactions attributed to compounds of similar chemical/biologic composition to other agents used in the study.
- Serious/non-healing wound/ulcer/bone fracture
- History of abdominal fistula/GI perforation/bowel obstruction/intraabdominal abscess within 28 days of treatment
- major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 therapy
- anticipation of need for major surgical procedures during study
- core biopsy within 7 days prior to Day 1 therapy
- Patients with clinically significant cardiovascular disease
- Evidence of bleeding diathesis or coagulopathy
- PT INR >1.5 unless the patient is on full-dose warfarin
- Use of thrombolytic agents within 1 month of study initiation
- Significant Proteinuria (>500mg/24h): Urine protein should be screened by random urinalysis for protein. If dipstick positive (>1+), 24-hour urine protein should be obtained and if >500mg/24 h, patient will be excluded.
- Uncontrolled intercurrent illness including but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study
- Pregnant women
- HIV-positive patients on combination antiretroviral therapy are ineligible because of potential for PK interactions with VEGF Trap
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I
Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1.
Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
|
Given intravenously
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria)
Time Frame: Up to 6 years
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions:Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions
|
Up to 6 years
|
Progression-free Survival (Bevacizumab- naïve Group)
Time Frame: 4 months
|
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Kaplan-Meier method will be used.Progression-free survival (Bevacizumab- naïve group) |
4 months
|
Progression-free Survival (Bevacizumab-treated Group)
Time Frame: 4 months
|
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Kaplan-Meier method will be used. Progression-free survival (Bevacizumab-treated group) |
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (Bevacizumab-naïve Group)
Time Frame: 12 months
|
Kaplan-Meier method will be used.
(Bevacizumab- naïve Group)
|
12 months
|
Overall Survival (Prior Bevacizumab Treated Group)
Time Frame: 12 months
|
Kaplan-Meier method will be used (Bevacizumab-naïve Group)
|
12 months
|
Time to Progression
Time Frame: 12 months
|
Kaplan-Meier method will be used.
|
12 months
|
Objective Stable Disease Rate
Time Frame: Up to 6 years
|
Up to 6 years
|
|
Number of Participants With Response (Bevacizumab-naïve Group)
Time Frame: Up to 6 years
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Stable disease for atleast 16 weeks |
Up to 6 years
|
Overall Survival (Bevacizumab-treated Group)
Time Frame: 6 months
|
Kaplan-Meier method will be used.
(Bevacizumab-treated Group)
|
6 months
|
Overall Survival (Bevacizumab-treated Group)
Time Frame: 12 months
|
Kaplan-Meier method will be used (Bevacizumab-treated Group)
|
12 months
|
Number of Participants With Response (Bevacizumab-treated Group)
Time Frame: Up to 6 years
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Stable disease for atleast 16 weeks |
Up to 6 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Malcolm Moore, University Health Network-Princess Margaret Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Disease Attributes
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Recurrence
- Rectal Neoplasms
- Colonic Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Aflibercept
- Endothelial Growth Factors
Other Study ID Numbers
- NCI-2009-00176
- N01CM62203 (U.S. NIH Grant/Contract)
- PHL-050 (Other Grant/Funding Number: N01CM62203)
- CDR0000518293 (Other Grant/Funding Number: N01CM62203)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IV Colon Cancer
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Adenocarcinoma | Advanced Colon Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage III Colon Cancer | Stage III Rectal CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditionsUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingRecurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditionsUnited States, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Gastric Cancer | Stage III Colon Cancer | Stage III Gastric Cancer | Stage III Rectal...United States
-
M.D. Anderson Cancer CenterBristol-Myers Squibb; Syntrix Biosystems, Inc.RecruitingMetastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedColorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Howard S. Hochster, MDRecruitingStage IV Colon Cancer AJCC v8 | Stage IVA Colon Cancer AJCC v8 | Stage IVB Colon Cancer AJCC v8 | Stage IVC Colon Cancer AJCC v8 | Metastatic Colon CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedRecurrent Colon Cancer | Recurrent Rectal Cancer | Stage IV A Bladder Cancer | Stage IV A Rectal Cancer | Stage IV B Colon Cancer | Stage IV B Rectal CancerUnited States
Clinical Trials on aflibercept
-
Regeneron PharmaceuticalsSanofiCompletedSolid TumorsUnited States, Canada
-
CR-CSSS Champlain-Charles-Le MoyneSanofi; Regeneron Pharmaceuticals; Quebec Clinical Research Organization in CancerTerminatedMetastatic Colorectal CancerCanada
-
Samsung Bioepis Co., Ltd.CompletedNeovascular Age-related Macular DegenerationCzechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
-
Alvotech Swiss AGActive, not recruitingNeovascular (Wet) AMDSlovakia, Czechia, Georgia, Japan, Latvia
-
Bioeq GmbHCompletedNeovascular Age-related Macular DegenerationBulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia
-
Regeneron PharmaceuticalsBayerCompletedNeovascular (Wet) Age-Related Macular DegenerationUnited States, Puerto Rico
-
SanofiRegeneron PharmaceuticalsCompletedNeoplasms | Cancer of the OvaryUnited States, France, Canada, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland
-
SanofiRegeneron PharmaceuticalsCompletedOvarian NeoplasmsUnited States, Italy, Sweden
-
SanofiRegeneron PharmaceuticalsCompletedNeoplasms, Lung | Pulmonary DiseasesUnited States, France, Canada
-
Regeneron PharmaceuticalsBayerActive, not recruitingType 2 Diabetes Mellitus | Diabetic Macular Edema | Type 1 Diabetes MellitusUnited States, Puerto Rico, Japan, United Kingdom, Canada, Czechia, Germany, Hungary